Translation of genomics into routine cardiological practice
Location: Marriott Munich Airport Hotel
Programme
DAY 1: 23 March 2023 - 14:00 - 18:45
Session 1 – Exemplars of translation into clinical practice and lessons learnt
Chaired by Chris O'Donnell and Heribert Schunkert
-
14:00-14:10 - Welcome – Introduction – Objectives of the Workshop
To prepare a short position paper describing:
• Current state of the art in genetic diagnostics and therapy
• Describe the current and future barriers to translation
• Propose an action plan to accelerate into routine care
by Chairpersons -
14:10-14:30 - What is precision cardiology? by Perry Elliott (London)
-
14:30-14:45 - PCSK9 and beyond by Ulf Landmesser (Berlin)
-
14:45-15:00 - Cardiac Amyloidosis by Thibaut Damy (Paris)
-
15:00-15:45 - Breakout Groups & Feedback/discussion (1): What does success look like? Moderators
Chaired by Filippo Crea and Paul Nioi
- 15:45-16:00 - Challenges for gene therapies: Delivery, durability and complications by Mauro Giacca (London)
- 16:00-16:15 - Gene therapy and Gene editing: Examples of successful translation by Christian Kupatt (Munich)
- 16:15-16:30 - RNA Therapeutics by Weinong Guo (Alnylam)
- 16:30-17:15 - Breakout Groups and Feedback/discussion (2):
- What are the main technical/biological barriers to be overcome?
- What can we do collectively to accelerate translation to patients?
Moderators
- 17:15-17:30 - Break
Chaired by Stefanie Dimmeler and Perry Elliott
-
17:30-17:45 - Debate: Polygenic risk scores are ready for application in routine cardiological practice. Pro: Maryam Kavousi (Rotterdam)
-
17:45-18:00 - Debate: Polygenic risk scores are ready for application in routine cardiological practice. Con: Heribert Schunkert (Munich)
-
18:00-18:45 - Panel and audience discussion: “How to overcome the gaps in translation – What are the critical issues?” All
Short rebuttal
VOTE BY AUDIENCE FOR/AGAINST THE MOTION -
18:45 - End of Day 1 – Outlook to Day 2
DAY 2: 24 March 2023 - 09:00 - 12:00
Chaired by Leticia Ferri and Eva Prescott
- 09:00-09:15 - Summary of Day 1 – Main outcomes from the breakout discussions by Chairpersons
- 09:15-09:45 - What is the landscape for approval and licensing of genomic therapies (EMA, MHRA)
- E. Zouridakis – Regulatory aspects – Genomic therapies
- Antonio Gomez-Outes (Spain)
- Emmanouil Zouridakis (UK MHRA)
- 09:45-10:45 - Breakout Groups and Feedback/discussion (3)
- How do we prioritize diseases for gene therapy?
- What are meaningful end-points in gene trials?
- What should professional societies/organizations be doing to prepare for precision diagnostics and therapy in CVD?
- Moderated by the chairpersons
- 10:45-11:00 - Break
- 11:00-11:45 - Wrap-up from breakout groups – Call for actions? Key take-home messages and recommendations in preparation of a publication by Chairpersons
- 12:00 - End of Day 2
A workshop chaired by
Doctor Christopher O'Donnell
Novartis
Doctor Leticia Ferri
BMS
